Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

Table 1 Baseline Patient Demographics

	Total patients with CM included (n = 177)
Sex
Male	29
Female	148
Mean Age (SD)
Male	42 (12.4)
(19-62 yrs)
Female	43 (13.7)
(18-74 yrs)

ISSN: 1129-2377